NCT04671771View on ClinicalTrials.gov

A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End Stage Renal Disease

NARecruitingINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

December 3, 2020

Primary Completion Date

December 1, 2027

Study Completion Date

July 1, 2029

Conditions
End Stage Renal Disease (ESRD)Kidney FailureChronic Renal DiseaseHemodialysis
Interventions
DEVICE

InnAVasc Arteriovenous Graft (IG) surgical implant

The InnAVasc Arteriovenous Graft (IG) is a hemodialysis vascular access graft, intended for implantation in the lower or upper arm using standard vascular techniques, in patients requiring hemodialysis

Trial Locations (11)

10029

RECRUITING

Mount Sinai Hospital, New York

10467

RECRUITING

Montefiore Medical Center, The Bronx

27607

RECRUITING

NC Heart and Vascular Research, LLC, Raleigh

27610

RECRUITING

WakeMed, Raleigh

29118

RECRUITING

Medical University of South Carolina, Orangeburg

34239

RECRUITING

Sarasota Memorial Hospital, Sarasota

40202

RECRUITING

University of Louisville, Louisville

75246

NOT_YET_RECRUITING

Baylor Heart and Vascular, Dallas

77030

RECRUITING

Houston Methodist Hopsital, Houston

85012

RECRUITING

AKDHC Medical Research Services, LLC, Phoenix

02115

RECRUITING

Brigham & Women's Hospital, Boston

All Listed Sponsors
lead

W.L.Gore & Associates

INDUSTRY